The two products in Xolegel CorePak are new Xebcort gel, a 1% hydrocortisone gel, and Xolegel (ketoconazole, USP) gel, 2%. Xebcort gel provides quick symptom relief and is presented as a 0.8 ounce tube designed for short term use to relieve itch.
Xolegel CorePak contains 45gm of Xolegel gel provided in three 15g tubes. In a long-term safety trial with Xolegel Gel, patients remained symptom free for up to eight weeks post-treatment.
Al Altomari, CEO of Barrier Therapeutics, said: "By providing the hydrocortisone and ketoconazole gels separately in one prescription, Xolegel CorePak encourages patients to comply with their physician's recommendations to better manage this chronic and common inflammatory skin condition."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index